comprehensive -WSS

comprehensive

author：fashion 2025-09-27 12:55:20 - browse：92939

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Will General Catalyst be the first of many hospital takeovers?

WSS

Diversify hospital leadership teams to protect BIPOC patient health

Victims of gun violence feel impacts long after bullet wound

Coercive sterilizations revealed by STAT prompt outrage

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Excited delirium, Elijah McClain, and emergency physicians

Victims of gun violence feel impacts long after bullet wound

focus

comprehensive

focus

New air purifier tech could be key to improving indoor air quality

The Sacklers, horror, and ‘The Fall of the House of Usher’

Novavax promises a turnaround & Lilly roils the obesity market

Biotech incubator Curie.Bio graduates its first startup

23andMe had bad news about my health. I wish a person had delivered it

STAT Virtual Event: ASCO Recap, Live!

Hollywood unions extend contract negotiations for actors

Senate panel clears PBM, hopsital reforms

Alkermes shareholders re

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

entertainment

How faith leaders like me can help address America's obesity epidemic

Diversify hospital leadership teams to protect BIPOC patient health

Cheap, fast test for Zika and dengue could cost just $1

Just how powerful is the placebo effect?

Study: New antibiotic targets gonorrhea as well as last existing drug

Senate panel clears PBM, hopsital reforms

focus

knowledge

focus

entertainment